scholarly journals Hippocampal Volume Reduction in Humans Predicts Impaired Allocentric Spatial Memory in Virtual-Reality Navigation

2015 ◽  
Vol 35 (42) ◽  
pp. 14123-14131 ◽  
Author(s):  
S. Guderian ◽  
A. M. Dzieciol ◽  
D. G. Gadian ◽  
S. Jentschke ◽  
C. F. Doeller ◽  
...  
Neurology ◽  
2018 ◽  
Vol 90 (10) ◽  
pp. e877-e886 ◽  
Author(s):  
Enchi Liu ◽  
Dai Wang ◽  
Reisa Sperling ◽  
Stephen Salloway ◽  
Nick C. Fox ◽  
...  

ObjectiveTo evaluate whether amyloid-related imaging abnormalities with edema/effusion (ARIA-E) observed in bapineuzumab clinical trials was associated with specific biomarker patterns.MethodsBapineuzumab, an anti-β-amyloid monoclonal antibody, was evaluated in patients with mild to moderate Alzheimer disease. Amyloid PET imaging, CSF biomarkers, or volumetric MRI (vMRI) were assessed.ResultsA total of 1,512 participants underwent one or more biomarker assessments; 154 developed incident ARIA-E. No differences were observed at baseline between ARIA-E and non-ARIA-E participants in brain amyloid burden by PET, the majority of vMRI measures, or CSF biomarkers, with the exception of lower baseline CSF Aβ42 in APOE ε4 noncarrier ARIA-E vs non-ARIA-E groups (bapineuzumab non-ARIA-E p = 0.027; placebo non-ARIA-E p = 0.012). At week 71, bapineuzumab-treated participants with ARIA-E vs non-ARIA-E showed greater reduction in brain amyloid PET, greater reductions in CSF phosphorylated tau (p-tau) (all comparisons p < 0.01), and total tau (t-tau) (all comparisons p < 0.025), and greater hippocampal volume reduction and ventricular enlargement (all p < 0.05). Greater reduction in CSF Aβ40 concentrations was observed for ARIA-E versus both non-ARIA-E groups (bapineuzumab/placebo non-ARIA-E p = 0.015/0.049). No group differences were observed at week 71 for changes in whole brain volume or CSF Aβ42.ConclusionsBaseline biomarkers largely do not predict risk for developing ARIA-E. ARIA-E was associated with significant longitudinal changes in several biomarkers, with larger reductions in amyloid PET and CSF p-tau and t-tau concentrations, and paradoxically greater hippocampal volume reduction and ventricular enlargement, suggesting that ARIA-E in bapineuzumab-treated cases may be related to increased Aβ efflux from the brain and affecting downstream pathogenic processes.


2016 ◽  
Vol 80 (4) ◽  
pp. 531-537 ◽  
Author(s):  
Beatrice Latal ◽  
◽  
Pratik Patel ◽  
Rabia Liamlahi ◽  
Walter Knirsch ◽  
...  

2020 ◽  
Vol 9 (5) ◽  
pp. 1355 ◽  
Author(s):  
Monia Cabinio ◽  
Federica Rossetto ◽  
Sara Isernia ◽  
Francesca Lea Saibene ◽  
Monica Di Cesare ◽  
...  

Due to the lack of pharmacological treatment for dementia, timely detection of subjects at risk can be of seminal importance for preemptive rehabilitation interventions. The aim of the study was to determine the usability of the smart aging serious game (SASG), a virtual reality platform, in assessing the cognitive profile of an amnestic mild cognitive impairment (aMCI) population, its validity in discriminating aMCI from healthy controls (HC), and in detecting hippocampal degeneration, a biomarker of clinical progression towards dementia. Thirty-six aMCI and 107 HC subjects were recruited and administered the SASG together with a neuropsychological evaluation. All aMCI and 30 HC subjects performed also an MRI for hippocampal volume measurement. Results showed good usability of the SASG despite the low familiarity with technology in both groups. ROC curve analyses showed similar discriminating abilities for SASG and gold standard tests, and a greater discrimination ability compared to non-specific neuropsychological tests. Finally, linear regression analysis revealed that the SASG outperformed the Montreal cognitive assessment test (MoCA) in the ability to detect neuronal degeneration in the hippocampus on the right side. These data show that SASG is an ecological task, that can be considered a digital biomarker providing objective and clinically meaningful data about the cognitive profile of aMCI subjects.


2019 ◽  
Vol 8 (10) ◽  
pp. 1516 ◽  
Author(s):  
Montana ◽  
Tuena ◽  
Serino ◽  
Cipresso ◽  
Riva

In recent years, virtual reality (VR) technologies have become widely used in clinical settings because they offer impressive opportunities for neurorehabilitation of different cognitive deficits. Specifically, virtual environments (VEs) have ideal characteristics for navigational training aimed at rehabilitating spatial memory. A systematic search, following PRISMA guidelines, was carried out to explore the current scenario in neurorehabilitation of spatial memory using virtual reality. The literature on this topic was queried, 5048 papers were screened, and 16 studies were included, covering patients presenting different neuropsychological diseases. Our findings highlight the potential of the navigational task in virtual environments (VEs) for enhancing navigation and orientation abilities in patients with spatial memory disorders. The results are promising and suggest that VR training can facilitate neurorehabilitation, promoting brain plasticity processes. An overview of how VR-based training has been implemented is crucial for using these tools in clinical settings. Hence, in the current manuscript, we have critically debated the structure and the length of training protocols, as well as a different type of exploration through VR devices with different degrees of immersion. Furthermore, we analyzed and highlighted the crucial role played by the selection of the assessment tools.


1998 ◽  
Vol 55 (5) ◽  
pp. 433 ◽  
Author(s):  
Michael D. Nelson ◽  
Andrew J. Saykin ◽  
Laura A. Flashman ◽  
Henry J. Riordan

2013 ◽  
Vol 211 (3) ◽  
pp. 189-194 ◽  
Author(s):  
Christina Josefa Herold ◽  
Marc Montgomery Lässer ◽  
Lena Anna Schmid ◽  
Ulrich Seidl ◽  
Li Kong ◽  
...  

2010 ◽  
Vol 17 (4) ◽  
pp. 599
Author(s):  
I. León ◽  
L. Roldán-Tapia ◽  
R. Cánovas ◽  
J.M. Cimadevilla ◽  
P. Serrano

2010 ◽  
Vol 33 (1) ◽  
pp. 48-53 ◽  
Author(s):  
Masami Goto ◽  
Osamu Abe ◽  
Tosiaki Miyati ◽  
Sachiko Inano ◽  
Naoto Hayashi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document